John Shine

Biography

John Shine was Garvan's Executive Director from 1990-2011. His name is known to most undergraduate biology students for his role in defining the Shine-Dalgarno gene sequence, which is responsible for the initiation and termination of protein-synthesis. John has a number of other significant scientific ‘firsts’ under his belt. He was a central figure in the cloning of the insulin and growth hormone genes; was the first to clone a human hormone gene; was responsible for cloning of an endorphin gene and was the first to demonstrate that hormone genes cloned in bacteria could be expressed in a biologically active form. He also determined the first sequence responsible for replication of a cancer-causing virus. John’s scientific career took off following a move, in 1975, to San Francisco. It was there that he cloned numerous genes as well as develop techniques to do this – he is a sole inventor on a patent for using phosphatase to direct the joining of DNA molecules. A three year appointment at California Biotechnology (CalBio) Inc company saw John guide it from a staff of some 15 scientists in 1984 to over 200 in 1987. During this period, Cal Bio developed several important new therapeutics including treatments for congestive heart failure, infant respiratory distress syndrome, and burns and general wound healing agents. At the same time, John developed an interest in the generation of functional diversity in the nervous system, a research area he established on joining the Garvan, with the DNA cloning of neuropeptide receptor subtypes.

Research Interest

Gene structure Gene regulation Transcription Translation Inherited genetic disorders